BMS’s Anti-LAG3 Drug Could Offer Safer Combo Partner To Opdivo Monotherapy Patients

Company Unveils Phase II/III Relatlimab Combo Data At ASCO

 
• By Alaric DeArment
Sun screen
BMS' anti-LAG3 antibody shows safety benefit combined with Opdivo compared with Opdivo/Yervoy • Source: Shutterstock

More from ASCO

More from Conferences